Akebia Therapeutics Inc (AKBA)
1.82
+0.03
(+1.68%)
USD |
NASDAQ |
Nov 21, 16:00
1.81
-0.01
(-0.55%)
After-Hours: 20:00
Akebia Therapeutics Gross Profit Margin (Quarterly): 62.16% for Sept. 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 62.16% |
June 30, 2024 | 60.94% |
March 31, 2024 | 64.41% |
December 31, 2023 | 66.79% |
September 30, 2023 | 57.17% |
June 30, 2023 | 69.34% |
March 31, 2023 | 49.53% |
December 31, 2022 | |
September 30, 2022 | 21.42% |
June 30, 2022 | 85.28% |
March 31, 2022 | 49.20% |
December 31, 2021 | 17.42% |
Date | Value |
---|---|
September 30, 2021 | 67.30% |
June 30, 2021 | 0.79% |
March 31, 2021 | 33.84% |
December 31, 2020 | -13.86% |
September 30, 2020 | 49.41% |
June 30, 2020 | -93.71% |
March 31, 2020 | 68.68% |
December 31, 2019 | 45.16% |
September 30, 2019 | 58.40% |
June 30, 2019 | 62.63% |
March 31, 2019 | 56.99% |
December 31, 2018 | 87.02% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-93.71%
Minimum
Jun 2020
85.28%
Maximum
Jun 2022
40.07%
Average
49.53%
Median
Mar 2023
Gross Profit Margin (Quarterly) Benchmarks
Corcept Therapeutics Inc | 98.43% |
Eli Lilly and Co | 81.02% |
Bioventus Inc | 67.32% |
NovaBay Pharmaceuticals Inc | 65.26% |
Palatin Technologies Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
Return on Assets | -20.36% |
Return on Invested Capital | -9.55K% |
Profit Margin (Quarterly) | -53.54% |
Operating Margin (Quarterly) | -33.41% |
Return on Net Operating Assets | -29.07% |